Understanding how certain antibodies can protect against pneumonia caused by Streptococcus pneumoniae
Official title: Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection
Funded at Florida State University · NIH-10977035 · Data updated 2026-11-12
This study is looking at how certain human antibodies can fight off Streptococcus pneumoniae, the bacteria that causes pneumonia, to help create better treatments for people at high risk, especially those dealing with antibiotic-resistant infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida State University NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project start | November 1, 2022 |
| Project end | October 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $684,721 |
| NIH project number | 5R01AI173084-04 |
| Project ID | NIH-10977035 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk for pneumococcal infections, such as those with diabetes, asthma, chronic obstructive pulmonary disease, cardiovascular disease, or HIV.
✕Less likely to help
Patients who are not at risk for pneumococcal infections or those who do not have underlying health conditions may not benefit from this research.
What this research studies
This research investigates the role of broadly protective human antibodies against Streptococcus pneumoniae, a major cause of pneumonia and other serious infections. The study aims to identify the structural features of these antibodies that enable them to effectively target and neutralize the bacteria. By focusing on conserved antigens that trigger a strong immune response, the research seeks to develop new therapies that could enhance protection against pneumococcal infections, especially in high-risk populations. Patients may benefit from improved treatment options that are effective against antibiotic-resistant strains of the bacteria.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that provide better protection against pneumococcal infections, particularly for vulnerable populations.
How similar studies have gone: Previous research has shown promise in developing broadly protective antibodies against various pathogens, indicating potential for success in this area as well.
Where this research is happening
-
Florida State University
Tallahassee, United States Active
Researchers
- Principal investigator: Mousa, Jarrod — Florida State University
- Study coordinator: Mousa, Jarrod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.